Alcobra Ltd said its drug to treat attention deficit disorder met the main goals of a late-stage trial, reducing the symptoms of the condition better than a sugar pill.
The study results were derived after the company excluded data from four patients who showed an extreme response to the placebo, Alcobra said in a statement.
The company said the study scored the drug, Metadoxine, on the same scale used in studies that evaluated other attention deficit hyperactivity disorder, or ADHD, drugs.
© 2021 Thomson/Reuters. All rights reserved.